Trial · NCT04598009
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
NCT04598009, Phase 2, Recruiting, University of California, San Francisco
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma. Trials, record NCT04598009. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04598009
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
- NCT number
- NCT04598009
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 25 participants, estimated
- Lead sponsor
- University of California, San Francisco
- Conditions
- Melanoma Stage III, Melanoma Stage IV
- Interventions
- Binimetinib, Imatinib
- First posted
- 2020-10-22
- Last updated
- 2026-08-18
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate (ORR) | Up to week 16 | Defined as complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). The ORR at stages 1 and 2 will be estimated using the method of Whitehead, and the p-values for testing the null hypothesis at each stage will use the method of Koyama \& Chen and 90% confidence interval will be reported. |
| Secondary | Proportion of participants with treatment-related adverse events (AE) | Up to 2 years | Proportion of participants with treatment-related AEs greater than grad2 as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 will be reported by toxicity. |
| Secondary | Median duration of response | Up to 2 years | Will estimate the probability-of-being-in-response function, assuming time to response is exponentially distributed. |
| Secondary | Progression-free survival (PFS) | Up to 2 years | Participants with an objective response will be followed for survival from initiation of study treatment until date of disease progression or death from any cause |
| Secondary | Overall survival (OS) | Up to 2 years | Participants will be followed from initiation of study treatment until date of disease progression or death from any cause and estimated using the Kaplan-Meier method to estimate the survival rate (95% CI) |
| Secondary | Clinical benefit rate (CBR) | Up to 2 years | Defined as CR, PR, or stable disease (SD) \>= 16 weeks by RECIST. CBR will be defined as the proportion of participants with CR, PR, or SD for \>= 16 weeks. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04598009
GET https://conductscience.org/api/trials/v1/NCT04598009/registered